CD44 and neoplasm: Since the first identification of breast cancer stem cells (BCSCs) from human tumor samples using CD44+/CD24− markers by Al-Hajj et al., the role of BCSCs in tumor progression and therapeutic resistance has been actively investigated to develop better anti-cancer treatment strategies [1], [2].